A hexanucleotide repeat modifies expressivity of X-linked dystonia parkinsonism.

Area of Science:

• Neurogenetics
• Molecular Neurology
• Genomic Instability

Background:

• X-linked dystonia parkinsonism (XDP) is a neurodegenerative disorder.
• A SINE-VNTR-Alu (SVA) retrotransposon insertion in the TAF1 gene causes XDP.
• A (CCCTCT)n hexanucleotide repeat within the SVA insertion is a potential modifier of XDP.

Purpose of the Study:

• To investigate the role of the hexanucleotide repeat number (RN) in modifying XDP expressivity.
• To correlate RN with clinical features, age at onset, and TAF1 expression.
• To assess the instability and somatic mosaicism of the hexanucleotide repeat.

Main Methods:

• Genotyping of the hexanucleotide repeat in 355 XDP patients.
• Correlation analysis of RN with age at onset, clinical manifestation, disease severity, and cognitive function.
• Segregation analysis, Southern blotting, and TAF1 expression analysis in blood RNA.

Main Results:

• RN inversely correlated with age at onset and TAF1 expression.
• RN positively correlated with disease severity and cognitive dysfunction.
• RN showed instability across generations and somatic mosaicism in the brain.

Conclusions:

• The hexanucleotide repeat acts as a genetic modifier of XDP expressivity.
• RN-dependent TAF1 repression may contribute to the neurological phenotype via somatic variability.
• This repeat influences disease progression and clinical presentation in XDP patients.